FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2737-2743 June 28, 2007 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

Public unease about industry's influence over clinical research has never been greater. Recent events have elevated concerns about financial ties among investigators, academic medical centers, and industry sponsors,^1,2,3,4 and disquieting findings have emerged about the legal relationships these entities form to conduct clinical trials.^5,6,7,8 Tort litigation brought by injured research subjects has accentuated the legal dimensions of clinical research relationships.^9,10,11

These areas of focus converged in Abney v. Amgen, an important case decided in March 2006 by the U.S. Court of Appeals for the Sixth Circuit.¹² The dispute centered on the legal obligation of an industry sponsor to provide clinical-trial . . . [Full Text of this Article]

The GDNF Clinical Trial

Plaintiffs' Claims and Court's Findings

Legal Context

Ethical Considerations

Recommendations for Academic Medical Centers

Source Information

From the Harvard School of Public Health (M.M.M.) and the Dana–Farber Cancer Institute, Children's Hospital, and Harvard Medical School (S.J.) — all in Boston.

This article has been cited by other articles:

• Iltis, A. S. (2008). Reviews in medical ethics.. J Law Med Ethics 36: 419-424